Introduction
============

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease specifically affecting the upper and lower motor neurons. Due to frequent early misdiagnosis, patients do not benefit from early drug intervention and clinical drug studies have been largely unsuccessful; a correct, early diagnosis of ALS is therefore crucial.

Such a clinical diagnosis, and study of the pathogenesis of ALS, could occur through analysis of changes to the cerebrospinal fluid (CSF) proteins. Insulin-like growth factor-1, vascular endothelial growth factor, transactive response DNA-binding protein 43, monocyte chemotactic protein 1 and other proteins have been reported as possible diagnostic indicators of ALS ([@b1-etm-0-0-3210]--[@b4-etm-0-0-3210]), but a definitive diagnostic indicator has yet to be established.

CSF quantitative proteomics, including differential in gel electrophoresis (DIGE) and isotope-coded affinity tags, have been reported in studies on Alzheimer\'s disease and Parkinson\'s disease ([@b5-etm-0-0-3210],[@b6-etm-0-0-3210]), but have not been widely used to investigate ALS. In 2005, a study by Ranganathan *et al* ([@b7-etm-0-0-3210]) was the first to investigate the CSF in ALS patients using surface-enhanced laser desorption/ionization (SELDI) technology and proteomics; three proteins, cystatin C, transthyretin and a carboxy-terminal fragment of the neuroendocrine protein 7B2, were screened and validated for their sensitivity and specificity as biomarkers. Other previous studies examined the CSF of ALS with two-dimensional gel electrophoresis, DIGE and SELDI ([@b8-etm-0-0-3210],[@b9-etm-0-0-3210]), but use of isobaric tags for relative and absolute quantitation (iTRAQ) technology in this context has not been reported, to the best of our knowledge.

The present study compared the CSF protein expression of ALS patients and healthy \[normal control \[NC\] group) patients using iTRAQ labeling and 2-dimensional liquid chromatography/tandem mass spectrometry (2D LC-MS/MS) technology, screened the resulting proteins and verified their differential expression by western blotting, in order to determine the most effective biomarkers for ALS diagnosis.

Patients and methods
====================

### Patients

#### ALS-A group

A total of 35 patients with ALS who presented to Huashan Hospital between March 2008 and October 2010 were selected for the study. Informed consent was obtained from all patients, or their families. Tension headache sufferers were selected as the normal control (NC) group. The other neurological disease (OND) group consisted of patients who, during clinical diagnosis, were subjected to a lumbar puncture; these patients suffered from conditions such as chronic non-inflammatory peripheral neuropathy, Parkinson\'s disease, spastic paraplegia and hydrocephalus. Patient ages ranged between 30 and 75 years old.

#### ALS-B group

A total of 10 cases of ALS were randomly selected from the ALS-A group and used to screen additional proteins.

#### CSF sample collection

Under fasting conditions, each patient was treated with the 2 ml local anesthetic lidocaine hydrochloride injection (2%; Shanghai Harvest Pharmaceutical Co., Ltd., Shanghai, China) and subjected to a lumbar puncture, from which 8--10 ml of CSF was collected. A volume of 4--5 ml of CSF was immediately centrifuged at 2,000 × g for 10 min; the resulting supernatant was collected and placed in 1.5 ml Eppendorf tubes (Eppendorf AG, Hamburg, Germany) at −80°C. The remaining CSF was used for biochemical and immunological detection, as subsequently described.

#### Determination of protein concentration using iTRAQ and 2D LC-MS/MS

Following the removal of 22 high-abundance proteins, including albumin and IgG, using ProteoMiner low abundance protein enrichment kits (Bio-Rad Laboratories, Inc., Hercules, CA, USA), protein quantification was conducted using a Protein Assay reagent kit (Bio-Rad Laboratories, Inc., Hercules, CA, USA) based on Bradford methods, according to manufacturer\'s protocol. iTRAQ labeling was performed according to the manufacturer\'s protocol (Applied Biosystems Life Technologies, Foster City, CA, USA). Briefly, 100 µg CSF proteins from the ALS and NC groups were precipitated with cold acetone (ratio of acetone:sample, 5:1) for 1 h at −20°C and resuspended in 20 µl dissolution buffer, respectively. Following centrifugation at 2,000 × g for 15 min and disposal of the supernatant, the precipitant was dissolved into 20 ul iTRAQ solution and 1 ul 1% sodium dodecyl sulfate (SDS). Subsequently, 1 ul cysteine sealing reagent was added for 10 min at room temperature. Proteins were trypsinized (Sigma-Aldrich, St. Louis, MO, USA) at 37°C overnight (ratio of enzyme:protein, 1:20). Peptides were labeled with iTRAQ regents for 1 h at room temperature. iTRAQ regents 113 and 118 were used to label the peptides from the NC and ALS groups, respectively. Following this, samples were mixed, desalted with Sep-Pak Vac C18 cartridges (Waters Corporation, Milford, MA, USA) and dried in a vacuum concentrator.

#### 2D LC-MS/MS analysis

High-performance liquid chromatography and time-of-flight mass spectrometry (API QSTAR XL Hybrid LC-MS/MS; Applied Biosystems Life Technologies) were used for protein separation and analysis. For 2D LC-MS/MS analysis, the iTRAQ-labeled mixed peptides were fractionated using strong cation exchange (SCX) chromatography on a 20AD HPLC system (Shimadzu Corporation, Kyoto, Japan) with a polysulfoethyl column (2.1×100 mm; 5 µm; 200 Å; The Nest Group, Inc., Southborough, MA, USA). Peptide mixture was reconstituted in Buffer A (SCXA), which contained 10 mM KH~2~PO~4~ in 25% acetonitrile (pH 2.6; Thermo Fisher Scientific, Waltham, MA, USA), and loaded onto the column. Peptides were separated at a flow rate of 200 µl/min for 60 min with a gradient of 0--80% Buffer B (Buffer A supplemented with 350 mM KCl) in Buffer A. Absorbances of 214 nm and 280 nm were identified by tandem mass spectrometry. A total of 20 SCX fractions were collected.

#### Protein identification

All data from tandem mass spectrometry were obtained from the UniProtKB/Swiss-Prot database using ProteinPilot 3.0 software (AB Sciex, Framingham, MA, USA), and the identification and quantification results were recorded. Search parameters were as follows: At least 1 matching peptide, a confidence interval (CI) of the peptide of \>95% (P\<0.05) and results in accordance with the peak of the spectrum.

#### Protein annotation and classification

The Database for Annotation, Visualization and Integrated Discovery (DAVID) was used for functional annotation of proteins and gene ontology (GO) was used to classify these proteins, including their involvement in biological processes, as cellular components and their molecular function.

#### Differential expression of proteins

Western blotting was performed to analyze differential protein expression in the CSF between the ALS-B and NC groups, in order to verify the iTRAQ results. A total of 1 ml CSF sample was added into a 3 kD ultrafiltration centrifugal tube (EMD Millipore, Billerica, CA, USA) for desalination and concentration. Protein concentrations were subsequently measured via the Bradford method using Bio-Rad protein assay reagent (Bio-Rad Laboratories, Inc.). A total of 20 µg protein was separated by 12% SDS polyacrylamide gel electrophoresis followed by electro-blotting onto a polyvinylidene difluoride membrane. The membrane was subsequently incubated with 5% nonfat dry milk in Tris-buffered saline at room temperature for 2 h, in order to block non-specific binding. Following this, the membrane was incubated with the following primary antibodies: Rabbit anti-human insulin-like growth factor II (IGF-2; l:1,250; ab9574); mouse anti-human leucine-rich α-2-glycoprotein 1 (LRG1; l:800; ab57992); and rabbit anti-human glutamate receptor 4 (GRIA4; 1:500; ab61171; all Abcam, Cambridge, UK), diluted in blocking buffer overnight at 4°C. The membrane was subsequently incubated with horseradish peroxidase-conjgated AffinPure goat anti-rabbit (KC-RB-035) and anti-mouse (KC-MM-035) immunoglobulin G (H+L) secondary antibodies (both 1:5,000; Shanghai Kangcheng Biotechnology Co., Ltd., Shanghai, China) diluted with nonfat dry milk and Tris-buffered saline and Tween 20 (TBST). After rinsing three times with TBST, the western blot protein band was detected using chemiluminescence, and the gray scales of the bands were quantified using software Image Lab 3.0 (Bio-Rad Laboratories, Inc.).

#### Statistical analysis

SPSS17.0 (SPSS, Inc., Chicago, IL, USA) was used for statistical analyses, GraphPad Prism 4 (GraphPad Software, Inc., La Jolla, CA, USA) was used to draw graphs and ProteinPilot 3.0 was used to detect the protein threshold \[where Unused ProtScore \>1.3 (95% CI)\]. An error (ProtScore) of 2.0 indicated a credible identified protein; an error of \>1.2 or \<0.8 indicated an identifiable significant difference (P\<0.05).

All data were normally distributed when examined with a one-sample Kolmogorov-Smirnov test. A t-test was used to compare two groups and data are expressed as the mean ± standard deviation; P\<0.05 was considered to indicate a statistically significant difference.

Correlation analysis used multiple linear regression analysis and the disaggregated data was assigned a conversion score, as follows: i) Gender: male, 1; and female, 2; ii) diagnostic level: diagnosed, 1; suspected, 2; suspected and clinically supported, 3; iii) involvement: medullary, 1; cervical, 2; and lumbar, 3.

Results
=======

### Clinical data

The average ages of the ALS-B and NC groups were 52.7±12.13 and 51.1±10.62 years old, respectively, and there were 6 men and 4 women in each group. No significant difference in age or gender balance between these groups was identified (P\>0.05).

The average ages of the ALS-A and OND groups were 52.80±11.98 and 51.17±12.44 years old, respectively, and there were 22 men and 13 women in the ALS-A group, and 11 men and 7 women in the OND group. No significant difference was identified in age or gender balance between these groups (P\>0.05). The protein concentration of CSF was 350.46±110.09 mg/l in the ALS-A group and 377.56±85.85 mg/l in the control group, with no significant difference revealed between the two (P\>0.05).

### CSF protein identification

iTRAQ and 2D-LC-MS/MS analyses were performed and used to analyze the protein content of the CSF in the ALS and NC groups. A total of 248 proteins were identified, and their names, the iTRAQ ratio (where available) and the UniProtKB/Swiss-Prot database accession number of 243 of these proteins are provided (95% CI; [Tables I](#tI-etm-0-0-3210){ref-type="table"} and [II](#tII-etm-0-0-3210){ref-type="table"}).

### Analyses of differential protein expression

A total of 35 differentially-expressed proteins were compared between the ALS and NC groups; of these, 14 were upregulated and 21 were downregulated ([Tables III](#tIII-etm-0-0-3210){ref-type="table"} and [IV](#tIV-etm-0-0-3210){ref-type="table"}). These proteins had a ProtScore between the values of \>1.2 and \<0.8, corresponding to P\<0.05.

### Sample data of specific differentially-expressed proteins

IGF-2 and LRG1 protein expression was decreased in the experimental groups, whereas GRIA4 expression was increased ([Fig. 1](#f1-etm-0-0-3210){ref-type="fig"}).

### DAVID results and the classification of proteins by biological role

The function of all identified proteins was analyzed using GO in conjunction with DAVID software. The most common biological roles of CSF proteins were in acute inflammation, damage response, protein maturation, inflammation, defense response, complement activation and other associated immune pathways ([Fig. 2](#f2-etm-0-0-3210){ref-type="fig"}).

### Classification by cellular localization

The most common localization of CSF proteins relative to cells included the extracellular domain, extracellular space, extracellular matrix and protein-lipid complexes ([Fig. 3](#f3-etm-0-0-3210){ref-type="fig"}).

### Classification by molecular function

The most common molecular functions of CSF proteins were endopeptidase, peptidase, enzyme and serine-type endopeptidase inhibitors, and antigen-, calcium- and heparin-binding proteins ([Fig. 4](#f4-etm-0-0-3210){ref-type="fig"}).

### Western blotting

A total of 3 candidate proteins were randomly selected to be examined by western blot analysis in the ALS and the NC groups ([Fig. 5](#f5-etm-0-0-3210){ref-type="fig"}); of these, IGF-2 was revealed to be significantly downregulated and GRIA4 was significantly upregulated in the ALS group when compared with the normal control group (P\<0.05; [Table V](#tV-etm-0-0-3210){ref-type="table"}), but LRG1 expression was not significantly altered (P=0.224; [Table V](#tV-etm-0-0-3210){ref-type="table"}). These proteins were also examined by western blot analysis in the ALS-A and OND groups, again demonstrating a significant downregulation of IGF-2 and a significant upregulation of GRIA4 in the ALS group compared with the OND group (P\<0.01; [Table VI](#tVI-etm-0-0-3210){ref-type="table"}), but no significant difference in LRG1 expression between these groups (P=0.196; [Table VI](#tVI-etm-0-0-3210){ref-type="table"}).

### Correlation between GRIA4 and gender

GRIA4 expression in the ALS-A group was significantly higher in male patients than in female patients (765,483±583,227 and 319,766±224,242, respectively; r=−0.574; P=0.003; [Fig. 6](#f6-etm-0-0-3210){ref-type="fig"}).

GRIA4 expression in the ALS-A group was also positively correlated with ALS clinical scores (r=0.487; P=0.017), indicating a negative correlation with clinical severity ([Fig. 7](#f7-etm-0-0-3210){ref-type="fig"}).

Discussion
==========

In the present study, 248 different low-abundance proteins were identified in human CSF and the details of these proteins were established in ALS patients. All proteins were subjected to GO analysis with DAVID software and were classified according to their involvement in biological processes, their cellular localization and their molecular function. Data indicated that the primary roles of these proteins were in the acute inflammatory response and injury response, that the proteins were predominantly localized to extracellular regions and that the majority of these proteins were endopeptidase and peptidase inhibitors. These data aid the understanding of CSF protein profiles in patients with ALS, and provide possible biomarkers of the disease. A screening of 35 of these proteins revealed significant differences in protein expression between the ALS and NC groups, primarily in inflammation-associated proteins, neurotrophic factors and signal transduction proteins.

IGF-2, GRIA4 and LRG1 were randomly selected to verify their differential expression in ALS patients using western blot analysis. Consistent with the results of the proteomic analysis, IGF-2 and GRIA4 expression was altered in the CSF of ALS patients, but there was no significant difference in LRG1 expression between the ALS and NC groups; this led to the conclusion that additional verification of the altered protein expression reported in the present study is necessary to confirm these proteomic results.

To confirm the expression specificity of IGF-2, GRIA4 and LRG1, expression levels of these proteins were compared in patients with ALS and patients with OND; IGF-2 expression was significantly decreased, but GRIA4 expression was significantly increased.

Alterations to protein expression are complex with regard to disease progression, age, gender and duration of illness; it was thus important to examine the correlation between alterations to protein expression and clinical features. Clinical data of 35 ALS patients was collected and were subjected to multiple linear regression analysis to reveal any confounding factors.

The clinical data in the present study revealed a higher male incidence of ALS (male to female ratio, 1.7:1), which was in support of a previous study; the 2009 European epidemiological study revealed a similar ratio of 1.4:1 ([@b10-etm-0-0-3210]). The present results demonstrated a correlation of GRIA4 expression with gender; male GRIA4 levels were 2.5-fold those of female levels (P\<0.01).

To the best of our knowledge, the association between glutamate receptor levels and clinical characteristics has not been studied; however, glutamate excitotoxicity damage is widely recognized in the pathogenesis of ALS. Fiszman *et al* ([@b11-etm-0-0-3210]) reported no significant correlation between glutamate ligand concentration in the CSF of patients with different severities of ALS, suggesting that glutamate is involved in the occurrence of ALS and not in the severity of the disease. Excitotoxicity of glutamate also requires the presence of a glutamate receptor, meaning that high expression of glutamate receptors may be responsible for the neuronal toxicity injury induced by glutamate. As the concentration of glutamate is increased in the CSF of ALS patients ([@b11-etm-0-0-3210]), and GRIA4 expression was increased in ALS in the current study, the high incidence of ALS may be associated with the expression of GRIA4.

In the present study, the ALS score was estimated using the ALSFRS-R scale; a lower score on this scale corresponded to more severe disease. A multivariate analysis indicated that GRIA4 expression was positively correlated with the ALS score, revealing a negative correlation with the severity of the disease. However, ALS patients with mild symptoms were selected, defined in accordance with a previous scoring system attributing a score \>25 to less severe ALS and scores of \<25 to moderate and severe phases of ALS ([@b12-etm-0-0-3210]). As the glutamate concentration is significantly increased in the CSF of ALS patients ([@b7-etm-0-0-3210]), glutamate is likely to be involved in the pathogenesis of the disease. From the present results, it was concluded that GRIA4 expression is likely to be involved in the pathogenesis of ALS, resulting in a negative feedback regulatory mechanism to subsequently reduce its expression. The glutamate receptor antagonist, riluzole, is effective in the early treatment of ALS ([@b13-etm-0-0-3210]). In conjunction with the present report suggesting the early-stage overexpression of GRIA4, these data indicate that early treatment with anti-glutamate-associated drugs may prove a useful therapeutic measure.

The multivariate analysis examining IGF-2 and LRG1 expression and the clinical data revealed no significant correlations. This may be attributable to the sample size of the present study being too small or too few clinical factors being included. Based on the standard deviation values, the expression levels of IGF-2 and LRG1 were relatively balanced, as compared with the standard deviation of the GRIA4 expression levels, which suggested that IGF-2 may be a valuable biomarker of ALS with higher credibility due to fewer interference factors.

In summary, GRIA4 expression varied based on gender and may be reflective of ALS severity, providing a meaningful reference value for the timing of treatment. Furthermore, IGF-2 may prove an effective diagnostic marker of ALS.
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![Sample data of 3 differentially-expressed proteins. GIVEECCFR, ALGHLDLSGNR and LQNILEQIVSVGK are enzyme-specific peptides. IGF-2, insulin-like growth factor II; GRIA4, glutamate receptor 4; LRG1, leucine-rich α-2-glycoprotein 1; iTRAQ, isobaric tags for relative and absolute quantitation.](etm-11-06-2095-g00){#f1-etm-0-0-3210}

![Identified cerebrospinal fluid proteins, classified by the biological processes that they are involved in. Activation of plasma proteins refers to this process in the acute inflammatory response.](etm-11-06-2095-g01){#f2-etm-0-0-3210}

![Identified cerebrospinal fluid proteins, classified by their cellular localization. Extracellular region refers to the space external to the outermost structure of the cell, indicating gene products that are not attached to the cell surface. Extracellular region part refers to any constituent part of the extracellular region, and is not used to specifically indicate gene products.](etm-11-06-2095-g02){#f3-etm-0-0-3210}

![Identified cerebrospinal fluid proteins, classified by their molecular function.](etm-11-06-2095-g03){#f4-etm-0-0-3210}

![Western blot analysis of the three candidate proteins, glutamate receptor 4 (GRIA4), leucine-rich α-2-glycoprotein 1 (LRG1) and insulin-like growth factor II (IGF-2). NC, normal control; ALS, amyotrophic lateral sclerosis; OND, other neurological disease.](etm-11-06-2095-g04){#f5-etm-0-0-3210}

![Correlation between GRIA4 and clinical features. GRIA4, glutamate receptor 4.](etm-11-06-2095-g05){#f6-etm-0-0-3210}

![Correlation of ALS value with GRIA4. ALS, amyotrophic lateral sclerosis; GRIA4, glutamate receptor 4; ALSFRS, ALS functional rating scale.](etm-11-06-2095-g06){#f7-etm-0-0-3210}

###### 

Proteins analyzed in the present study.

  Unused ProtScore (CL, %)   Proteins detected, n   Proteins prior to grouping, n   Distinct peptides, n   Spectra identified, n   \% of total spectra
  -------------------------- ---------------------- ------------------------------- ---------------------- ----------------------- ----------------------------------------------------
  \>2.0 (99)                 211                    285                             18106                  37075                   33.8
  \>1.3 (95)                 248                    347                             19568                  38823                   35.4^[a](#tfn1-etm-0-0-3210){ref-type="table-fn"}^
  \>0.47 (66)                294                    448                             21271                  40761                   37.2

Cutoff applied at an unused protein score of \>1.3. CL, confidence level.

###### 

Proteins in ALS and NC groups by cerebrospinal fluid.

  Protein name                                                             iTRAQ ratio (ALS/NC)                             Accession no.   
  ------------------------------------------------------------------------ ------------------------------------------------ --------------- --
  Serum albumin                                                            0.9262                                           sp\|P02768\|    
  Complement C4-A                                                          1.0317                                           sp\|P0C0L4\|    
  Complement C3                                                            1.0003                                           sp\|P01024\|    
  Transthyretin                                                            1.0717                                           sp\|P02766\|    
  α-1-antitrypsin                                                          0.7250                                           sp\|P01009\|    
  α-2-macroglobulin                                                        0.9938                                           sp\|P01023\|    
  Serotransferrin                                                          0.8150                                           sp\|P02787\|    
  Fibronectin                                                              1.0084                                           sp\|P02751\|    
  Apolipoprotein A1                                                        1.0930                                           sp\|P02647\|    
  Ig γ1 chain C region                                                     0.9304                                           sp\|P01857\|    
  Apolipoprotein E                                                         1.1323                                           sp\|P02649\|    
  Gelsolin                                                                 1.0509                                           sp\|P06396\|    
  Apolipoprotein A-IV                                                      1.1446                                           sp\|P06727\|    
  Clusterin                                                                1.0969                                           sp\|P10909\|    
  Cystatin C                                                               1.0671                                           sp\|P01034\|    
  Vitamin D-binding protein                                                0.8710                                           sp\|P02774\|    
  Contactin-1                                                              1.0430                                           sp\|Q12860\|    
  Complement factor                                                        1.0036                                           sp\|P08603\|    
  Pigment epithelium-derived factor                                        0.9803                                           sp\|P36955\|    
  Secretogranin-1                                                          1.0670                                           sp\|P05060\|    
  Ceruloplasmin                                                            0.8720                                           sp\|P00450\|    
  Serum albumin                                                            1.0588                                           sp\|P51693\|    
  Haptoglobin                                                              0.6926                                           sp\|P00738\|    
  Secretogranin-3                                                          1.1640                                           sp\|Q8WXD2\|    
  Antithrombin-III                                                         0.8452                                           sp\|P01008\|    
  Chromogranin-A                                                           1.0098                                           sp\|P010645\|   
  α-1-B glycoprotein                                                       0.9835                                           sp\|P04217\|    
  β-Ala-His dipeptidase                                                    1.1591                                           sp\|Q96KN2\|    
  Neuronal cell adhesion molecule                                          1.0097                                           sp\|Q92823\|    
  Ig γ2 chain C region                                                     1.0383                                           sp\|P01859\|    
  Monocyte differentiation antigen CD14                                    0.8775                                           sp\|P08571\|    
  Fibrinogen α chain                                                       1.0375                                           sp\|P02671\|    
  α-1-antichymotrypsin                                                     0.9855                                           sp\|P01011\|    
  Neurosecretory protein VGF                                               1.0510                                           sp\|015240\|    
  α-2-HS-glycoprotein                                                      1.0036                                           sp\|P02765\|    
  Angiotensinogen                                                          1.0014                                           sp\|P01019\|    
  Ig α1 chain C region                                                     1.0096                                           sp\|P01876\|    
  Collagen α-1(I) chain                                                    1.0412                                           sp\|P02452\|    
  Plasminogen                                                              0.8738                                           sp\|P00747\|    
  Kininogen-1                                                              0.8529                                           sp\|P01042\|    
  Fibulin-1                                                                0.9324                                           sp\|P23142\|    
  Hemoglobin subunit β                                                     1.4623                                           sp\|P68871\|    
  Prostaglandin-H2 D-isomerase                                             0.9310                                           sp\|P41222\|    
  *N*-acetyllactosaminide β-1,3-*N*-acetylglucosaminyltransferase          1.0294                                           sp\|O43505\|    
  Neuronal pentraxin receptor                                              1.0815                                           sp\|O95502\|    
  Hemopexin                                                                0.8432                                           sp\|P02790\|    
  Retinol-binding protein 4                                                0.9796                                           sp\|P02753\|    
  Apolipoprotein D                                                         0.9616                                           sp\|P05090\|    
  Ectonucleotide pyrophosphatase/phosphodiesterase family member 2         0.9689                                           sp\|Q13822\|    
  β-2-glycoprotein 1                                                       0.9413                                           sp\|P02749\|    
  Carboxypeptidase E                                                       1.0193                                           sp\|P16870\|    
  Collagen α-2(I) chain                                                    1.0000                                           sp\|P08123\|    
  Calsyntenin-1                                                            1.1224                                           sp\|O94985\|    
  Vitronectin                                                              0.8401                                           sp\|P04004\|    
  Nucleobindin-1                                                           1.0513                                           sp\|Q02818\|    
  Ig µ chain C region                                                      0.8467                                           sp\|P01871\|    
  Ig κ chain C region                                                      1.0135                                           sp\|P01834\|    
  Ig γ3 chain C region                                                     0.9289                                           sp\|P01860\|    
  Extracellular superoxide dismutase (Cu-Zn)                               1.0356                                           sp\|P08294\|    
  Cathepsin D                                                              0.9478                                           sp\|P07339\|    
  Afamin                                                                   1.0176                                           sp\|P43652\|    
  Complement component C7                                                  0.9460                                           sp\|P10643\|    
  Apolipoprotein A-II                                                      1.2524                                           sp\|P02652\|    
  Contactin-2                                                              1.0433                                           sp\|Q02246\|    
  Inter-α-trypsin inhibitor heavy chain                                    1.0549                                           sp\|Q14624\|    
  Neural cell adhesion molecule 1                                          1.0091                                           sp\|P13591\|    
  EGF-containing fibulin-like extracellular matrix protein                 0.9392                                           sp\|Q12805\|    
  Ig λ chain C regions                                                     1.0045                                           sp\|P01842\|    
  Complement component C9                                                  0.7597                                           sp\|P02748\|    
  Neural cell adhesion molecule L1-like protein                            1.0405                                           sp\|O00533\|    
  Procollagen C-endopeptidase enhancer 1                                   1.0410                                           sp\|Q15113\|    
  Mimecan                                                                  0.9845                                           sp\|P20774\|    
  Fibrinogen β chain                                                       1.0713                                           sp\|P02675\|    
  Hemoglobin subunit α                                                     1.5451                                           sp\|P69905\|    
  ProSAAS                                                                  1.0492                                           sp\|Q9UHG2\|    
  Neuronal pentraxin-1                                                     1.1167                                           sp\|Q15818\|    
  β-2-microglobulin                                                        1.0138                                           sp\|P61769\|    
  Collagen α-1(VI) chain                                                   1.0602                                           sp\|P12109\|    
  Neural cell adhesion molecule 2                                          0.9561                                           sp\|O15394\|    
  Leucine-rich α-2-glycoprotein                                            0.6430                                           sp\|P02750\|    
  Insulin-like growth factor-binding protein 2                             0.9574                                           sp\|P18065\|    
  Insulin-like growth factor-binding protein 6                             0.9883                                           sp\|P24592\|    
  Protein kinase C-binding protein NELL2                                   0.9929                                           sp\|Q99435\|    
  Keratin, type II cytoskeletal 1                                          0.9729                                           sp\|P04264\|    
  Dickkopf-related protein 3                                               1.0396                                           sp\|Q9UBP4\|    
  Ig κ chain V--III region                                                 0.9945                                           sp\|P01623\|    
  Complement C1r subcomponent                                              0.9240                                           sp\|P00736\|    
  Prothrombin                                                              0.9113                                           sp\|P00734\|    
  Dystroglycan                                                             1.0292                                           sp\|Q14118\|    
  Tetranectin                                                              0.9282                                           sp\|P05452\|    
  α-2-antiplasmin                                                          0.9126                                           sp\|P08697\|    
  Complement factor B                                                      0.8143                                           sp\|P00751\|    
  Cartilage acidic protein 1                                               1.0590                                           sp\|Q9NQ79\|    
  Peptidylglycine α-amidating monooxygenase                                0.8763                                           sp\|P19021\|    
  Major prion protein                                                      1.0478                                           sp\|P04156\|    
  Zinc-α-2-glycoprotein                                                    0.7912                                           sp\|P25311\|    
  Neuroendocrine protein 7B2                                               1.1447                                           sp\|P05408\|    
  Multiple epidermal growth factor-like domains 8                          0.9706                                           sp\|Q7Z7M0\|    
  Insulin-like growth factor-binding protein 7                             1.0327                                           sp\|Q16270\|    
  SPARC                                                                    0.8425                                           sp\|P09486\|    
  Trypsin-1                                                                1.2077                                           sp\|P07477\|    
  Secretogranin-2                                                          0.9307                                           sp\|P13521\|    
  Voltage-dependent calcium channel subunit α~2~δ-1                        0.9343                                           sp\|P54289\|    
  Pyruvate kinase isozymes M1/M2                                           1.0611                                           sp\|P14618\|    
  Cadherin 13                                                              1.0163                                           sp\|P55290\|    
  GM2 Ganglioside activator                                                1.0083                                           sp\|P17900\|    
  Fibrinogen γ chain                                                       1.0925                                           sp\|P02679\|    
  Extracellular matrix protein 1                                           1.0849                                           sp\|Q16610\|    
  Collagen α-1(XVIII) chain                                                1.0000                                           sp\|P39060\|    
  Cadherin-2                                                               1.0560                                           sp\|P19022\|    
  Semaphorin 7A                                                            0.9433                                           sp\|O75326\|    
  Ig κ chain V--II region GM607                                            0.9526                                           sp\|P06309\|    
  Ig λ chain V--III region LOI                                             0.7060                                           sp\|P01617\|    
  Transmembrane protein 132A                                               1.1680                                           sp\|Q24JP5\|    
  Metalloproteinase inhibitor 2                                            0.9855                                           sp\|P16035\|    
  Osteopontin                                                              1.0354                                           sp\|P10451\|    
  Kallikrein-6                                                             0.9713                                           sp\|Q92876\|    
  Sex hormone-binding globulin                                             0.6051                                           sp\|P04278\|    
  Actin, cytoplasmic 1                                                     0.8566                                           sp\|P60709\|    
  Ig γ-4 chain C region                                                    1.1808                                           sp\|P01861\|    
  Protein FAM3C                                                            0.9182                                           sp\|Q92520\|    
  Chorionic somatomammotropin hormone                                      0.5234                                           sp\|P01243\|    
  Keratin, type I cytoskeletal 9                                           0.9161                                           sp\|P35527\|    
  Limbic system-associated membrane protein                                0.9398                                           sp\|Q13449\|    
  Phospholipid transfer protein                                            1.1687                                           sp\|P55058\|    
  Ig heavy chain V--III region BRO                                         0.9650                                           sp\|P01766\|    
  SPARC-like protein 1                                                     0.9325                                           sp\|Q14515\|    
  Fructose-bisphosphate aldolase                                           0.9490                                           sp\|P04075\|    
  *N*-acetylmuramoyl-L-alanine amidase                                     0.9820                                           sp\|Q96PD5\|    
  Complement C1s subcomponent                                              0.9598                                           sp\|P09871\|    
  Ig κ chain V--IV region B17                                              0.8581                                           sp\|P06314\|    
  Lumican                                                                  1.0259                                           sp\|P51884\|    
  Opioid-binding protein/cell adhesion molecule                            0.8758                                           sp\|Q14982\|    
  Ribonuclease pancreatic                                                  0.7527                                           sp\|P07998\|    
  Ig κ chain V--III region CLL                                             0.8486                                           sp\|P04207\|    
  Immunoglobulin superfamily member 8                                      0.8751                                           sp\|Q969P0\|    
  78-kDa glucose-regulated protein                                         0.9751                                           sp\|P11021\|    
  Protein AMBP                                                             0.7950                                           sp\|P02760\|    
  Coagulation factor V                                                     1.0938                                           sp\|P12259\|    
  Histidine-rich glycoprotein                                              0.9048                                           sp\|P04196\|    
  Ig heavy chain V--III region KOL                                         0.9839                                           sp\|P01772\|    
  L-lactate dehydrogenase B chain                                          0.9649                                           sp\|P07195\|    
  Complement component C6                                                  0.9164                                           sp\|P13671\|    
  Ephrin type-A receptor 4                                                 0.9178                                           sp\|P54764\|    
  Cerebellin-3                                                             1.0609                                           sp\|Q6UW01\|    
  Proenkephalin A                                                          1.0079                                           sp\|P01210\|    
  Insulin like growth factor binding protein 4                             0.8461                                           sp\|P22692\|    
  Apolipoprotein C-III                                                     1.1181                                           sp\|P02656\|    
  Trypsin −3                                                               1.1478                                           sp\|P35030\|    
  Transforming growth factor-β-induced protein ig-h3                       1.0709                                           sp\|Q15582\|    
  IgG Fc-binding protein                                                   1.0775                                           sp\|Q9Y6R7\|    
  Plasma serine protease inhibitor                                         0.9604                                           sp\|P05154\|    
  Coagulation factor XII                                                   0.9422                                           sp\|P00748\|    
  Biotinidase                                                              1.2970                                           sp\|P43251\|    
  Ig κ chain V--III region VG (Fragment)                                   1.09987                                          sp\|P04433\|    
  Collagen α-3(VI) chain                                                   0.9422                                           sp\|P00748\|    
  Neuroserpin                                                              1.0459                                           sp\|Q99574\|    
  Keratin, type I cytoskeletal 10                                          0.8858                                           sp\|P13645\|    
  Fibulin-5                                                                0.9587                                           sp\|Q9UBX5\|    
  Receptor-type tyrosine-protein phosphatase S                             1.1670                                           sp\|Q13332\|    
  Complement factor I                                                      0.8627                                           sp\|P05156\|    
  Ig heavy chain V--III region TRO                                         1.1189                                           sp\|P01762\|    
  Basement membrane-specific heparan sulfate proteoglycan core protein     0.9080                                           sp\|P98160\|    
  α-1 acid glycoprotein 1                                                  0.7355                                           sp\|P02763\|    
  Chitinase-3-like protein 1                                               0.9904                                           sp\|P36222\|    
  Cell adhesion molecule 3                                                 0.8572                                           sp\|Q8N126\|    
  Galectin-3-binding protein                                               0.9876                                           sp\|Q08380\|    
  Ig heavy chain V--III region POM                                         1.0712                                           sp\|P01774\|    
  Endonuclease domain-containing 1 protein                                 1.0166                                           sp\|P01776\|    
  Ig λ chain V--I region HA                                                1.0838                                           sp\|P01779\|    
  Complement C1q subcomponent subunit B                                    1.0301                                           sp\|P02746\|    
  Leucine-rich repeat-containing protein 4B                                1.0174                                           sp\|Q9NT99\|    
  Peroxiredoxin-2                                                          1.6278                                           sp\|P32119\|    
  Glyceraldehyde-3-phosphate dehydrogenase                                 1.2506                                           sp\|P04406\|    
  Serum paraoxonase/arylesterase 1                                         0.8635                                           sp\|P27169\|    
  Calcium/calmodulin-dependent protein kinase type II α chain              1.1677                                           sp\|Q9UQM7\|    
  Fibrillin-1                                                              0.2204                                           sp\|P35555\|    
  Complement C2                                                            0.9405                                           sp\|P06681\|    
  Cell growth regulator with EF hand domain protein 1                      1.3740                                           sp\|Q99674\|    
  Myopalladin                                                              0.6801                                           sp\|Q86TC9\|    
  Neuronal growth regulator 1                                              1.0667                                           sp\|Q7Z3B1\|    
  Serum amyloid A-4 protein                                                1.0645                                           sp\|P35542\|    
  Protocadherin Fat 2                                                      1.1409                                           sp\|Q9NYQ8\|    
  Cathepsin F                                                              1.1142                                           sp\|Q9UBX1\|    
  DNA repair protein RAD50                                                 0.9463                                           sp\|Q92878\|    
  α-enolase                                                                1.1591                                           sp\|P06733\|    
  Insulin-like growth factor II                                            0.4053                                           sp\|P01344\|    
  Ig λ chain V--III region SH                                              1.0399                                           sp\|P01714      
  Reelin                                                                   1.1149                                           sp\|P78509\|    
  Pregnancy-specific β-1-glycoprotein 1                                    0.7522                                           sp\|P11464\|    
  Retinoic acid receptor responder protein 2                               1.0850                                           sp\|Q99969\|    
  Lymphocyte antigen 6H                                                    1.0322                                           sp\|O94772\|    
  Receptor-type tyrosine-protein phosphatase N2                            1.0020                                           sp\|Q92932\|    
  Multimerin-2                                                             1.0029                                           sp\|Q9H8L6\|    
  Apolipoprotein L1                                                        0.9537                                           sp\|O14791\|    
  Ig κ chain V--I region Roy                                               ^[a](#tfn2-etm-0-0-3210){ref-type="table-fn"}^   sp\|P01608\|    
  Neurofascin                                                              1.0305                                           sp\|O94856\|    
  V-type proton ATPase                                                     0.8780                                           sp\|Q15904\|    
  Heparin cofactor 2                                                       1.0087                                           sp\|P05546\|    
  Plasma glutamate carboxypeptidase                                        1.0663                                           sp\|Q9Y646\|    
  Hypoxia upregulated protein 1                                            1.0213                                           sp\|Q9Y4L1\|    
  Ig κ chain V--I region Ka                                                0.9834                                           sp\|P01603\|    
  Protein DJ-1                                                             1.2886                                           sp\|Q99497\|    
  Laminin subunit γ-1                                                      0.8128                                           sp\|P11047\|    
  Cell surface glycoprotein MUC18                                          0.7681                                           sp\|P43121\|    
  Neuroendocrine convertase 2                                              1.2290                                           sp\|P16519\|    
  Inter-α-trypsin inhibitor heavy chain H5                                 0.9165                                           sp\|Q86UX2\|    
  Exostosin-like 2                                                         0.9342                                           sp\|Q9UBQ6\|    
  Metalloproteinase inhibitor 1                                            1.0673                                           sp\|P01033\|    
  Immunoglobulin J chain                                                   1.0429                                           sp\|P01591\|    
  Ig κ chain V--I region BAN                                               ^[a](#tfn2-etm-0-0-3210){ref-type="table-fn"}^   sp\|P04430\|    
  Ig κ chain V--I region DEE                                               1.0241                                           sp\|P01597\|    
  Ig κ chain V--I region Wes                                               0.8814                                           sp\|P01611\|    
  Serum amyloid A-1 protein                                                0.6516                                           sp\|P02735\|    
  Glutamate receptor 4                                                     1.3098                                           sp\|P48058\|    
  Amyloid β A4                                                             1.0164                                           sp\|P05067\|    
  Zinc finger protein                                                      0.9751                                           sp\|B1APH4\|    
  Nidogen-2                                                                1.0441                                           sp\|Q14112\|    
  72-kDa type IV collagenase                                               0.8378                                           sp\|P08253\|    
  WAP, kazal, immunoglobulin, Kunitz and NTR domain-containing protein 2   1.0204                                           sp\|Q8TEU8\|    
  Kallistatin                                                              0.8933                                           sp\|P29622\|    
  45-kDa calcium-binding protein                                           1.0575                                           sp\|Q9BRK5\|    
  Tissue α-L-fucosidase                                                    1.1211                                           sp\|P04066\|    
  protein Cut A                                                            1.0521                                           sp\|O60888\|    
  Ig heavy chain V--I region                                               0.9126                                           sp\|P06326\|    
  Ig heavy chain V--I region                                               0.9126                                           sp\|P06326\|    
  γ-glutamyl hydrolase                                                     1.2209                                           sp\|Q92820\|    
  Complement component C8 γ chain                                          0.9202                                           sp\|P07360\|    
  Phosphatidylethanolamine-binding protein 1                               1.1293                                           sp\|P30086\|    
  Thy-1 membrane glycoprotein                                              0.7535                                           sp\|P04216\|    
  Cell adhesion molecule 4                                                 0.9868                                           sp\|Q8NFZ8\|    
  Sjoegren syndrome/scleroderma autoantigen 1                              0.9615                                           sp\|O60232\|    
  Uncharacterized protein C6orf170                                         1.1061                                           sp\|Q96NH3\|    
  *N*-acetylglucosamine-1-phosphotransferase subunit γ                     1.0938                                           sp\|Q9UJJ9\|    
  Testican-2                                                               1.2140                                           sp\|Q92563\|    
  Fructose-bisphosphate aldolase C                                         ^[a](#tfn2-etm-0-0-3210){ref-type="table-fn"}^   sp\|P09972\|    
  Lysozyme C                                                               0.8222                                           sp\|P61626\|    
  V-type proton ATPase subunit D                                           1.2915                                           sp\|Q9Y5K8\|    
  Coagulation factor XI                                                    ^[a](#tfn2-etm-0-0-3210){ref-type="table-fn"}^   sp\|P03951\|    
  Complement C1q subcomponent subunit C                                    0.8441                                           sp\|02747\|     
  Dermcidin                                                                0.7257                                           sp\|P81605\|    
  Ig κ chain V--II region RPMI 6410                                        0.7960                                           sp\|P06310\|    
  Hemoglobin subunit δ                                                     ^[a](#tfn2-etm-0-0-3210){ref-type="table-fn"}^   sp\|P06310\|    
  Titin                                                                    0.9960                                           sp\|Q8WZ42\|    
  Tumor protein 63                                                         0.7445                                           sp\|Q9H3D4\|    
  Cysteine-rich with EGF-like domain protein 1                             1.0219                                           sp\|Q96HD1\|    
  Putative α-1-antitrypsin-related protein                                 0.8877                                           sp\|P20848\|    
  Scrapie-responsive protein 1                                             1.0576                                           sp\|O75711\|    

Not identified. ALS, amyotrophic lateral sclerosis; NC, normal control; iTRAQ, isobaric tags for relative and absolute quantitation.

###### 

Proteins decreased in ALS group.

  Protein                                 Ratio of ALS vs. control   Accession no.
  --------------------------------------- -------------------------- ---------------
  α-1-antitrypsin α1                      0.7250                     sp\|P01009\|
  Haptoglobin                             0.6926                     sp\|P00738\|
  Complement component 9                  0.7597                     sp\|P02748\|
  Leucine-rich α-2-glycoprotein           0.6430                     sp\|P02750\|
  Zinc-α-2-glycoprotein                   0.7912                     sp\|P25311\|
  Sex hormone-binding globulin            0.6051                     sp\|P04278\|
  Chorionic somatomammotropin hormone 1   0.5234                     sp\|P01243\|
  Ribonuclease pancreatic                 0.7527                     sp\|P07998\|
  Protein AMBP                            0.7950                     sp\|P02760\|
  α-1-acid glycoprotein 1                 0.7355                     sp\|P02763\|
  Fibrillin-1                             0.2204                     sp\|P35555\|
  Myopalladin                             0.6801                     sp\|Q86TC9\|
  Insulin-like growth factor II           0.4053                     sp\|P01344\|
  Pregnancy-specific β-1-glycoprotein 1   0.7522                     sp\|P43251\|
  Cell surface glycoprotein MUC18         0.7681                     sp\|P43121\|
  Serum amyloid A protein                 0.6516                     sp\|P02735\|
  Thy-1 membrane glycoprotein             0.7535                     sp\|P04216\|
  Dermcidin                               0.7257                     sp\|P81605\|
  Ig λ chain V--III region LOI            0.7060                     sp\|P01617\|
  Ig κ chain V--II region RPMI 6410       0.7960                     sp\|P06310\|
  Tumor protein 63                        0.7444                     sp\|Q9H3D4\|

ALS, amyotrophic lateral sclerosis.

###### 

Increased proteins in ALS group.

  Protein                                               Ratio of ALS vs. control   Accession no.
  ----------------------------------------------------- -------------------------- ---------------
  Peroxiredoxin-2                                       1.6278                     sp\|P32119\|
  Glutamate receptor 4                                  1.3097                     sp\|P02735\|
  Apolipoprotein A-II                                   1.2523                     sp\|P48058\|
  Hemoglobin subunit α                                  1.5451                     sp\|P69905\|
  Trypsin-1                                             1.2076                     sp\|P69905\|
  Biotinidase                                           1.2970                     sp\|P43251\|
  Hemoglobin subunit β                                  1.4623                     sp\|P68871\|
  Glyceraldehyde-3-phosphate dehydrogenase              1.2505                     sp\|P04406\|
  Cell growth regulator with EF hand domain protein 1   1.3748                     sp\|Q99674\|
  Protein DJ-1                                          1.2886                     sp\|Q99497\|
  Neuroendocrine convertase 2                           1.2294                     sp\|P16519\|
  γ-glutamyl hydrolase                                  1.2209                     sp\|Q92820\|
  Testican-2                                            1.2140                     sp\|Q92563\|
  V-type proton ATPase subunit D                        1.2915                     sp\|Q9Y5K8\|

ALS, amyotrophic lateral sclerosis.

###### 

Western blotting results of ALS-B and NC groups.

  Protein   Molecular weight, KDa   ALS group (n=10)   NC group (n=10)   P-value
  --------- ----------------------- ------------------ ----------------- -----------------------------------------------------
  IGF-2     7.5                     225700±126090      436857±212550     0.017^[a](#tfn6-etm-0-0-3210){ref-type="table-fn"}^
  GRIA4     102                     715730±432220      305796±130600     0.016^[a](#tfn6-etm-0-0-3210){ref-type="table-fn"}^
  LRG1      38                      1278000±702040     1807000±1115500   0.224

Data are presented as the mean ± standard deviation.

P\<0.05 vs. NC group. ALS, amyotrophic lateral sclerosis; NC, normal control; IGF-2, insulin-like growth factor II; GRIA4, glutamate receptor 4; LRG1, leucine-rich α-2-glycoprotein 1.

###### 

Western blotting results of ALS-A and OND groups.

  Protein   ALS group (n=35)   OND group (n=18)   P-value
  --------- ------------------ ------------------ -----------------------------------------------------
  IGF-2     222200±123648      452500±255620      0.002^[a](#tfn8-etm-0-0-3210){ref-type="table-fn"}^
  GRIA4     608502±519012      200100±150810      0.002^[a](#tfn8-etm-0-0-3210){ref-type="table-fn"}^
  LRG1      1097255±961025     746070±703690      0.196

Data are presented as the mean ± standard deviation.

P\<0.01 vs. OND group. ALS, amyotrophic lateral sclerosis; OND, other neurological disease; IGF-2, insulin-like growth factor II; GRIA4, glutamate receptor 4; LRG1, leucine-rich α-2-glycoprotein 1.
